International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?

Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target f...

Full description

Saved in:

Bibliographic Details
Published in	Lipids in health and disease Vol. 22; no. 1; pp. 67 - 10
Main Authors	Calice-Silva, Viviane, Muenz, Daniel, Wong, Michelle M. Y., McCullough, Keith, Charytan, David, Reichel, Helmut, Robinson, Bruce, Stengel, Benedicte, Massy, Ziad A., Pecoits-Filho, Roberto
Format	Journal Article
Language	English
Published	London BioMed Central 25.05.2023 BioMed Central Ltd BMC
Subjects	Adult Age groups Angioplasty Aortic aneurysms Biomedical and Life Sciences Cardiovascular disease Cardiovascular diseases Cholesterol Cholesterol, LDL Chronic kidney disease Chronic kidney failure Clinical medicine Clinical Nutrition Diabetes Drug dosages Drug therapy Dyslipidemia Dyslipidemias Dyslipidemias - epidemiology Heart attacks Hemoglobin High density lipoprotein Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemia Kidney diseases Laboratories LDL-C Life Sciences Lipidology Lipids Lipids management Low density lipoprotein Medical Biochemistry Metabolic disorders Nephrology Patients Practice guidelines (Medicine) Renal Insufficiency, Chronic - drug therapy Statins Statistics Stroke Treatment Outcome United States Vein & artery diseases United States Brazil France Germany United States > US Chronic kidney disease LDL-C Lipids management Statins Dyslipidemia Chronic kidney disease; Dyslipidemia; LDL-C; Lipids management; Statins
Online Access	Get full text
ISSN	1476-511X 1476-511X
DOI	10.1186/s12944-023-01833-z

Cover

Abstract	Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. Methods We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014–2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. Results LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France ( p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients ( p < 0.0001) and differed significantly by country ( p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage ( p = 0.09 LDL-C and p = 0.24 statin use). Between 7—23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7–17% of nephrologists believed that LDL-C should be < 70 mg/dL. Conclusion There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment.
AbstractList	Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. Methods We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014–2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. Results LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France ( p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients ( p < 0.0001) and differed significantly by country ( p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage ( p = 0.09 LDL-C and p = 0.24 statin use). Between 7—23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7–17% of nephrologists believed that LDL-C should be < 70 mg/dL. Conclusion There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. Abstract Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. Methods We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014–2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. Results LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7—23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7–17% of nephrologists believed that LDL-C should be < 70 mg/dL. Conclusion There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. Background: In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. Methods: We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014–2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. Results: LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7—23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7–17% of nephrologists believed that LDL-C should be < 70 mg/dL. Conclusion: There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014-2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7--23% of untreated patients in each country had LDL-C [greater than or equal to] 160 mg/dL. Only 7-17% of nephrologists believed that LDL-C should be < 70 mg/dL. There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care.BACKGROUNDIn contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care.We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014-2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age.METHODSWe analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014-2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age.LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7-23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7-17% of nephrologists believed that LDL-C should be < 70 mg/dL.RESULTSLLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7-23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7-17% of nephrologists believed that LDL-C should be < 70 mg/dL.There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment.CONCLUSIONThere is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. BackgroundIn contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care.MethodsWe analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014–2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age.ResultsLLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7—23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7–17% of nephrologists believed that LDL-C should be < 70 mg/dL.ConclusionThere is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014-2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7-23% of untreated patients in each country had LDL-C ≥ 160 mg/dL. Only 7-17% of nephrologists believed that LDL-C should be < 70 mg/dL. There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a lipid profile upon diagnosis of chronic kidney disease (CKD) and treating all patients older than 50 years without defining a target for lipid levels. We evaluated multinational practice patterns for lipid management in patients with advanced CKD under nephrology care. Methods We analyzed lipid-lowering therapy (LLT), LDL- cholesterol (LDL-C) levels, and nephrologist-specified LDL-C goal upper limits in adult patients with eGFR < 60 ml/min from nephrology clinics in Brazil, France, Germany, and the United States (2014-2019). Models were adjusted for CKD stage, country, cardiovascular risk indicators, sex, and age. Results LLT treatment differed significantly by country, from 51% in Germany to 61% in the US and France (p = 0.002) for statin monotherapy. For ezetimibe with or without statins, the prevalence was 0.3% in Brazil to 9% in France (< 0.001). Compared with patients not taking lipid-lowering therapy, LDL-C was lower among treated patients (p < 0.0001) and differed significantly by country (p < 0.0001). At the patient level, the LDL-C levels and statin prescription did not vary significantly by CKD stage (p = 0.09 LDL-C and p = 0.24 statin use). Between 7--23% of untreated patients in each country had LDL-C [greater than or equal to] 160 mg/dL. Only 7-17% of nephrologists believed that LDL-C should be < 70 mg/dL. Conclusion There is substantial variation in practice patterns regarding LLT across countries but not across CKD stages. Treated patients appear to benefit from LDL-C lowering, yet a significant proportion of hyperlipidemia patients under nephrologist care are not receiving treatment. Keywords: Chronic kidney disease, Dyslipidemia, Lipids management, LDL-C, Statins
ArticleNumber	67
Audience	Academic
Author	Muenz, Daniel Charytan, David Massy, Ziad A. Pecoits-Filho, Roberto Reichel, Helmut Robinson, Bruce Stengel, Benedicte Calice-Silva, Viviane Wong, Michelle M. Y. McCullough, Keith
Author_xml	– sequence: 1 givenname: Viviane surname: Calice-Silva fullname: Calice-Silva, Viviane organization: Pro-Kidney Foundation, University of Joinville’s Region - UNIVILLE – sequence: 2 givenname: Daniel surname: Muenz fullname: Muenz, Daniel organization: Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School – sequence: 3 givenname: Michelle M. Y. surname: Wong fullname: Wong, Michelle M. Y. organization: Division of Nephrology, Department of Medicine, University of British Columbia – sequence: 4 givenname: Keith surname: McCullough fullname: McCullough, Keith organization: Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School – sequence: 5 givenname: David surname: Charytan fullname: Charytan, David organization: Nephrology Division, New York University Grossman School of Medicine – sequence: 6 givenname: Helmut surname: Reichel fullname: Reichel, Helmut organization: Nephrological Center Villingen-Schwenningen – sequence: 7 givenname: Bruce surname: Robinson fullname: Robinson, Bruce organization: Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School – sequence: 8 givenname: Benedicte surname: Stengel fullname: Stengel, Benedicte organization: Université Paris Saclay, Université Versailles Saint-Quentin en Yvelines, Institut National de La Santé Et de La Recherche Médicale (Inserm), Centre de Recherche en Epidémiologie Et Santé Des Populations (CESP), Equipe Epidémiologie Clinique – sequence: 9 givenname: Ziad A. surname: Massy fullname: Massy, Ziad A. organization: Université Paris Saclay, Université Versailles Saint-Quentin en Yvelines, Institut National de La Santé Et de La Recherche Médicale (Inserm), Centre de Recherche en Epidémiologie Et Santé Des Populations (CESP), Equipe Epidémiologie Clinique, Department of Nephrology, CHU Ambroise Paré, APHP – sequence: 10 givenname: Roberto surname: Pecoits-Filho fullname: Pecoits-Filho, Roberto email: Roberto.Pecoits@ArborResearch.org organization: Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/37231413$$D View this record in MEDLINE/PubMed https://hal.science/hal-04190781$$DView record in HAL
BookMark	eNp9U01v1DAQjVAR_YA_wAFZ4lIOKbbjfHGpqgroSitxAYmbNXFmsy6JvdjZVtt_xL9kstvSD6HKB1vj997MPM0cJnvOO0ySt4KfCFEVH6OQtVIpl1nKRZVl6c2L5ECoskhzIX7uPXjvJ4cxXnIueVkUr5L9rJSZUCI7SP7M3IjBwWi9g56tApjRGmQrGKd4ZH7B2k3s7cq2OFhgAzjocEA3MusmmKVnZNd2XDKzDN5Zw37Z1uGGtTYiRGRr12JgDlf03ftuwwwE_MRsZHZkox2QjZ4FvLJ4zbo15emtQwoYP1CedltbPH2dvFxAH_HN7X2U_Pjy-fv5RTr_9nV2fjZPTaHkmBZly-sqlxU0TYOZEFyBMW1tshoVV1gXDSjgAqh90zR1XTYGoMG6anJEbrKjZLbTbT1c6lWwA4SN9mD1NuBDpyGQRz1qSXQAUxisQRUAVdVwCSIvWwk1V5PW6U5rtW4GbA1ZFaB_JPr4x9ml7vyVFlxS4QUnhQ87heUT3sXZXE8xrkTNy0pcCcIe32YL_vca46gHGw32PTj066hlJTkXRSEn2fdPoJd-TWPQb1EluSbL7B7VAXVr3cJTkWYS1Wdlzstc5UVFqJP_oOhMA2NoZBeW4o8I7x668q-tu6kkQLUDmOBjDLjQxo7bMSBl25M7eloAvVsATQugtwugb4gqn1Dv1J8lZTtSJLDrMNy78QzrLzuwHD0
CitedBy_id	crossref_primary_10_3390_biomedicines12102402 crossref_primary_10_1186_s12944_023_01991_0 crossref_primary_10_3390_biomedicines12102377 crossref_primary_10_2174_0113816128285148240122112045 crossref_primary_10_1053_j_ajkd_2024_11_003 crossref_primary_10_1007_s00108_024_01813_0
Cites_doi	10.1056/NEJMoa043545 10.1681/ASN.2022020135 10.1016/S0140-6736(11)60739-3 10.1038/ki.2013.181 10.1093/eurheartj/ehab509 10.1016/j.jacc.2010.01.020 10.1161/CIRCINTERVENTIONS.122.012103 10.1161/01.CIR.0000143892.84582.60 10.1053/j.ajkd.2008.11.025 10.1016/j.ekir.2019.07.014 10.1093/eurheartj/ehz455 10.1016/j.endonu.2010.06.003 10.1053/j.ajkd.2016.03.414 10.1007/s40620-021-01086-y 10.1152/ajprenal.00099.2005 10.1016/S2213-8587(16)30156-5 10.1038/s41581-018-0072-9 10.3390/toxins8120376 10.1016/j.jacc.2018.11.002 10.1016/S0140-6736(13)60595-4 10.1038/nrneph.2011.62 10.1056/NEJMoa0810177 10.5527/wjn.v1.i6.184
ContentType	Journal Article
Contributor	Pisoni, Ron Narita, Ichiei Jacquelinet, Christian Asahi, Koichi Sesso, Ricardo Hoshino, Junichi Port, Friedrich Sukul, Nidhi Fliser, Danilo Young, Eric Wong, Michelle Zee, Jarcy Speyer, Elodie Duttlinger, Johannes Lonnemann, Gerhard Calice-Silva, Viviane de Pinho, Natalia Alencar Combe, Christian Wada, Takashi Lopes, Antonio Massy, Ziad Perlman, Rachel Yamagata, Kunihiro
Contributor_xml	– sequence: 1 givenname: Antonio surname: Lopes fullname: Lopes, Antonio – sequence: 2 givenname: Christian surname: Combe fullname: Combe, Christian – sequence: 3 givenname: Christian surname: Jacquelinet fullname: Jacquelinet, Christian – sequence: 4 givenname: Ziad surname: Massy fullname: Massy, Ziad – sequence: 5 givenname: Johannes surname: Duttlinger fullname: Duttlinger, Johannes – sequence: 6 givenname: Danilo surname: Fliser fullname: Fliser, Danilo – sequence: 7 givenname: Gerhard surname: Lonnemann fullname: Lonnemann, Gerhard – sequence: 8 givenname: Takashi surname: Wada fullname: Wada, Takashi – sequence: 9 givenname: Kunihiro surname: Yamagata fullname: Yamagata, Kunihiro – sequence: 10 givenname: Ron surname: Pisoni fullname: Pisoni, Ron – sequence: 11 givenname: Viviane surname: Calice-Silva fullname: Calice-Silva, Viviane – sequence: 12 givenname: Ricardo surname: Sesso fullname: Sesso, Ricardo – sequence: 13 givenname: Elodie surname: Speyer fullname: Speyer, Elodie – sequence: 14 givenname: Natalia Alencar surname: de Pinho fullname: de Pinho, Natalia Alencar – sequence: 15 givenname: Koichi surname: Asahi fullname: Asahi, Koichi – sequence: 16 givenname: Junichi surname: Hoshino fullname: Hoshino, Junichi – sequence: 17 givenname: Ichiei surname: Narita fullname: Narita, Ichiei – sequence: 18 givenname: Rachel surname: Perlman fullname: Perlman, Rachel – sequence: 19 givenname: Friedrich surname: Port fullname: Port, Friedrich – sequence: 20 givenname: Nidhi surname: Sukul fullname: Sukul, Nidhi – sequence: 21 givenname: Michelle surname: Wong fullname: Wong, Michelle – sequence: 22 givenname: Eric surname: Young fullname: Young, Eric – sequence: 23 givenname: Jarcy surname: Zee fullname: Zee, Jarcy
Copyright	The Author(s) 2023 2023. The Author(s). COPYRIGHT 2023 BioMed Central Ltd. 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License
Copyright_xml	– notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: COPYRIGHT 2023 BioMed Central Ltd. – notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License
CorporateAuthor	on behalf of CKDopps Investigators CKDopps Investigators
CorporateAuthor_xml	– name: on behalf of CKDopps Investigators – name: CKDopps Investigators
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI RC3 7X8 1XC VOOES 5PM DOA
DOI	10.1186/s12944-023-01833-z
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Genetics Abstracts MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database MEDLINE
Database_xml	– sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Anatomy & Physiology Statistics
EISSN	1476-511X
EndPage	10
ExternalDocumentID	oai_doaj_org_article_2b99aac6ce9a46aa88b02a157d2a904c PMC10210460 oai_HAL_hal_04190781v1 A750754568 37231413 10_1186_s12944_023_01833_z
Genre	Journal Article
GeographicLocations	United States Brazil France Germany United States--US
GeographicLocations_xml	– name: United States – name: Germany – name: France – name: Brazil – name: United States--US
GroupedDBID	--- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AAFWJ AAHBH AAJSJ AASML ABDBF ABUWG ACGFO ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 LK8 M1P M48 M7P M~E O5R O5S OK1 OVT P2P P6G PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF FRP NPM PMFND 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ K9. P64 PKEHL PQEST PQUKI RC3 7X8 1XC 2VQ 4.4 AHSBF EJD H13 IPNFZ RIG VOOES 5PM
ID	FETCH-LOGICAL-c642t-67d098528abbbe31104accd9c39e404e96ba4a01a413cbb997bcaabe98b5ee0c3
IEDL.DBID	M48
ISSN	1476-511X
IngestDate	Wed Aug 27 01:24:17 EDT 2025 Tue Sep 30 17:13:57 EDT 2025 Fri Sep 12 12:56:21 EDT 2025 Mon Sep 08 13:21:04 EDT 2025 Fri Jul 25 19:24:40 EDT 2025 Tue Jun 17 21:33:30 EDT 2025 Tue Jun 10 20:17:39 EDT 2025 Wed Feb 19 02:02:37 EST 2025 Thu Apr 24 22:58:56 EDT 2025 Wed Oct 01 00:25:11 EDT 2025 Sat Sep 06 07:34:23 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	Chronic kidney disease LDL-C Lipids management Statins Dyslipidemia Chronic kidney disease; Dyslipidemia; LDL-C; Lipids management; Statins
Language	English
License	2023. The Author(s). Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c642t-67d098528abbbe31104accd9c39e404e96ba4a01a413cbb997bcaabe98b5ee0c3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-1062-0073 0000-0002-0360-573X 0000-0001-7692-3096 0000-0003-0749-1714 0000-0002-0255-6710 0000-0001-9025-5178 0000-0001-5771-5996 0000-0002-5904-7570 0000-0002-7407-0410
OpenAccessLink	https://www.proquest.com/docview/2827110273?pq-origsite=%requestingapplication%
PMID	37231413
PQID	2827110273
PQPubID	42587
PageCount	10
ParticipantIDs	doaj_primary_oai_doaj_org_article_2b99aac6ce9a46aa88b02a157d2a904c pubmedcentral_primary_oai_pubmedcentral_nih_gov_10210460 hal_primary_oai_HAL_hal_04190781v1 proquest_miscellaneous_2820016620 proquest_journals_2827110273 gale_infotracmisc_A750754568 gale_infotracacademiconefile_A750754568 pubmed_primary_37231413 crossref_citationtrail_10_1186_s12944_023_01833_z crossref_primary_10_1186_s12944_023_01833_z springer_journals_10_1186_s12944_023_01833_z
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2023-05-25
PublicationDateYYYYMMDD	2023-05-25
PublicationDate_xml	– month: 05 year: 2023 text: 2023-05-25 day: 25
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Lipids in health and disease
PublicationTitleAbbrev	Lipids Health Dis
PublicationTitleAlternate	Lipids Health Dis
PublicationYear	2023
Publisher	BioMed Central BioMed Central Ltd BMC
Publisher_xml	– name: BioMed Central – name: BioMed Central Ltd – name: BMC
References	RT Gansevoort (1833_CR2) 2013; 382 M Tonelli (1833_CR9) 2004; 110 L Mariani (1833_CR7) 2016; 68 BR Chaitman (1833_CR20) 2022; 15 CJ Ferro (1833_CR11) 2018; 14 JI Shin (1833_CR22) 2022; 33 ZA Massy (1833_CR8) 2021; 34 MJ Koren (1833_CR21) 2009; 53 ND Vaziri (1833_CR12) 2006; 290 1833_CR4 F Mach (1833_CR5) 2020; 41 R Scarpioni (1833_CR23) 2012; 1 N Florens (1833_CR14) 2016; 8 SM Grundy (1833_CR24) 2019; 73 ZA Massy (1833_CR3) 2013; 84 C Wanner (1833_CR16) 2005; 353 SM Grundy (1833_CR6) 2019; 139 PM Ridker (1833_CR10) 2010; 55 WC Herrington (1833_CR18) 2016; 4 C Baigent (1833_CR15) 2011; 377 1833_CR25 J Mesquita (1833_CR13) 2010; 57 V Krane (1833_CR1) 2011; 7 H Wu (1833_CR27) 2021; 74 JL Lopez-Sendon (1833_CR19) 2022; 43 ZA Massy (1833_CR26) 2019; 4 BC Fellstrom (1833_CR17) 2009; 360
References_xml	– volume: 353 start-page: 238 issue: 3 year: 2005 ident: 1833_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa043545 – volume: 33 start-page: 1767 issue: 9 year: 2022 ident: 1833_CR22 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2022020135 – volume: 377 start-page: 2181 issue: 9784 year: 2011 ident: 1833_CR15 publication-title: Lancet doi: 10.1016/S0140-6736(11)60739-3 – volume: 84 start-page: 451 issue: 3 year: 2013 ident: 1833_CR3 publication-title: Kidney Int doi: 10.1038/ki.2013.181 – volume: 43 start-page: 148 issue: 2 year: 2022 ident: 1833_CR19 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab509 – volume: 55 start-page: 1266 issue: 12 year: 2010 ident: 1833_CR10 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2010.01.020 – volume: 15 issue: 8 year: 2022 ident: 1833_CR20 publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.122.012103 – volume: 110 start-page: 1557 issue: 12 year: 2004 ident: 1833_CR9 publication-title: Circulation doi: 10.1161/01.CIR.0000143892.84582.60 – volume: 53 start-page: 741 issue: 5 year: 2009 ident: 1833_CR21 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2008.11.025 – volume: 4 start-page: 1546 issue: 11 year: 2019 ident: 1833_CR26 publication-title: Kidney Int Rep doi: 10.1016/j.ekir.2019.07.014 – volume: 41 start-page: 111 issue: 1 year: 2020 ident: 1833_CR5 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehz455 – volume: 57 start-page: 440 issue: 9 year: 2010 ident: 1833_CR13 publication-title: Endocrinol Nutr doi: 10.1016/j.endonu.2010.06.003 – volume: 68 start-page: 402 issue: 3 year: 2016 ident: 1833_CR7 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2016.03.414 – volume: 34 start-page: 1467 issue: 5 year: 2021 ident: 1833_CR8 publication-title: J Nephrol doi: 10.1007/s40620-021-01086-y – ident: 1833_CR4 – volume: 290 start-page: F262 issue: 2 year: 2006 ident: 1833_CR12 publication-title: Am J Physiol Renal Physiol doi: 10.1152/ajprenal.00099.2005 – volume: 4 start-page: 829 year: 2016 ident: 1833_CR18 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(16)30156-5 – ident: 1833_CR25 – volume: 139 start-page: e1046 issue: 25 year: 2019 ident: 1833_CR6 publication-title: Circulation – volume: 14 start-page: 727 issue: 12 year: 2018 ident: 1833_CR11 publication-title: Nat Rev Nephrol doi: 10.1038/s41581-018-0072-9 – volume: 8 start-page: 376 issue: 12 year: 2016 ident: 1833_CR14 publication-title: Toxins (Basel) doi: 10.3390/toxins8120376 – volume: 73 start-page: 3168 issue: 24 year: 2019 ident: 1833_CR24 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2018.11.002 – volume: 382 start-page: 339 issue: 9889 year: 2013 ident: 1833_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(13)60595-4 – volume: 7 start-page: 385 issue: 7 year: 2011 ident: 1833_CR1 publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2011.62 – volume: 360 start-page: 1395 issue: 14 year: 2009 ident: 1833_CR17 publication-title: N Engl J Med doi: 10.1056/NEJMoa0810177 – volume: 1 start-page: 184 issue: 6 year: 2012 ident: 1833_CR23 publication-title: World J Nephrol doi: 10.5527/wjn.v1.i6.184 – volume: 74 start-page: 219 issue: 3 year: 2021 ident: 1833_CR27 publication-title: Can J Hosp Pharm
SSID	ssj0020766
Score	2.3743954
Snippet	Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend... In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend conducting a... Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend... BackgroundIn contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend... Background: In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend... Abstract Background In contrast to guidelines related to lipid therapy in other areas, 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines...
SourceID	doaj pubmedcentral hal proquest gale pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	67
SubjectTerms	Adult Age groups Angioplasty Aortic aneurysms Biomedical and Life Sciences Cardiovascular disease Cardiovascular diseases Cholesterol Cholesterol, LDL Chronic kidney disease Chronic kidney failure Clinical medicine Clinical Nutrition Diabetes Drug dosages Drug therapy Dyslipidemia Dyslipidemias Dyslipidemias - epidemiology Heart attacks Hemoglobin High density lipoprotein Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemia Kidney diseases Laboratories LDL-C Life Sciences Lipidology Lipids Lipids management Low density lipoprotein Medical Biochemistry Metabolic disorders Nephrology Patients Practice guidelines (Medicine) Renal Insufficiency, Chronic - drug therapy Statins Statistics Stroke Treatment Outcome United States Vein & artery diseases
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QFQcsjUNCAEBwgauI4js0FLYhqhSgnKvVm2V4vXcFmq2YXafuP-JfMOA8IFXDhGjvJ2DP2fGPPg7GnQvqSShqnwVuVCqlsajn3KYLfbG5dxUOMSjv6KKfH4v1JefJLqS_yCWvTA7cTd8Cd1tZ66YO2QlqrlMu4zctqxq3OhKfdF9VYb0x1phZa57IPkVHyoEGtJkSK-glNZ1UU6cVIDcVs_cOefPWUXCIv483LbpO_3Z1GlXR4k93osCRM2jHcYldCvcv2JjXa0cstPIPo3RmPzXfZtaPuEn2PfR-dAkIfJwVnMdVm3cBqDrMt4s-2eKyF5eAiA4saukysDdARLvg2uS58WczqsIXuvgcoNO0c6oCiEgkA8jB7BYsGFmugevawXkEbNgOfN5RqC0kDss6X-J-2zlPz-jY7Pnz36e007So2pB7tmHUqq1mmVcmVdc6FAqGFsN7PtC90EJkIWjorbJZbVJ3eIWcr5611QStXhpD54g7bqVd1uMfAZ57yJvLSSwRNhVMETISWXkk311YlLO8ZaHyXzpyqanw10axR0rRMN8h0E5luLhL2YnjnrE3m8dfeb0guhp6UiDs-QPE0nXiaf4lnwp6TVBnaLpA8b7uoBxwkJd4yE0RsFaFYHND-qCcucz9qfoJyOSJmOvlg6FkmENVVKv-W4zd6sTXdXtQYNKor5ATi1IQ9Hprp8-RfV4fVJvYh8C95lrC7rZQPvyoqtAGQYQlTI_kf0TJuqRenMVM51Y2nm_eEveyXyk-6_jzz9__HzD9g13lc8GXKy322sz7fhIcIINfuUdwrfgAv528m priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELfYkBAvCDY-AgMdCMEDRMuH4zi8TAUxVYjxxKS-WbbrbhU0KU2L1P1H_JfcOR9VmNhr7Cbn3vnud_Z9MPaaC5tRS-PQWS1DLqQOdZLYEMFvNNMmT5zPSjv7Jsbn_Mskm7QHbnUbVtnpRK-op5WlM_JjdA1yNFVobU-Wv0LqGkW3q20LjT12O0aoQlKdT3YOF_rookuUkeK4RtvGeYhWCh1omabh1cAY-Zr9vWbeu6TAyOuo83rw5D83qN4wnd5n91pECaNGBB6wW648YIejEr3pxRbegI_x9IfnB-zOWXuVfsj-DM4CocuWgqUvuFnWUM1gukUU2rSQ1bDoA2VgXkJbj7UGOsgF25TYhR_zaem20N76ACWoraB0KDCeAKA4sw8wr2G-BupqD-sKmuQZuNhQwS0kDchHX-B3mm5P9clDdn76-funcdj2bQgtejPrUOTTqJBZIrUxxqXINa6tnRY2LRyPuCuE0VxHsUYDao0pitxYrY0rpMmci2z6iO2XVemeMLCRpeqJSWYFQqfUSIInvBBWCjMrtAxY3DFQ2baoOfXW-Km8cyOFapiukOnKM11dBexd_5tlU9LjxtkfSS76mVSO2z-oVheq3d0qwUVobYV1heZCaylNlOg4y6eJLiJuA_aWpEqR0kDyrG5zH3CRVH5LjRC35YRlcUFHg5m42e1g-BXK5YCY8eiromcRR2yXy_h3jO_oxFa1GqlWu_0TsJf9ML2eouxKV238HHIBRBIF7HEj5f2n0hw9AWRYwORA_ge0DEfK-aWvV07d4-n-PWDvu62yo-v___zTm5fxjN1N_FbOwiQ7Yvvr1cY9R4C4Ni-8FvgLgRtl0Q priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZokRAXBC2PQEEDQnCAqFnHcWwuaEFUK0Q5Uak3y_Z62xVsttrsIm3_Ef-SGeeBQgGJa-Ik48zY_sae-Yax50L6gkoap8FblQqpbGo59ymC32xmXclDzEo7_iwnJ-LjaXHaJoXVXbR7dyQZZ-o4rJU8rHFlEiLFNQbdX5Xn6eUOu16QAaEVn_Bx72ahZy679Jg_PjdYgiJTfz8f75xTOORVrHk1ZPK3c9O4HB3dZrdaHAnjRvF32LVQ7bH9cYU-9GILLyBGdsYt8z1247g9QN9nPwY7gNDlSMFFpNmsaljOYLpF7NkUjrWw6MNjYF5By8JaA23fgm-IdeHrfFqFLbRnPUBpaSuoAppJFAAouuwNzGuYr4Fq2cN6CU3KDJxtiGYLRQPyzBf4nabGU_32Ljs5-vDl_SRtqzWkHn2YdSrLaaZVwZV1zoUcYYWw3k-1z3UQmQhaOitsNrK4bHrntC6dt9YFrVwRQubze2y3WlbhAQOfeeJM5IWXCJhypwiUCC29km6mrUrYqFOg8S2VOVXU-GaiS6OkaZRuUOkmKt1cJuxV_8xFQ-Txz9bvyC76lkTCHS8sV2emHdOGYyes9dIHbYW0VimXcTsqyim3OhM-YS_JqgxNFSiet23GA3aSSLfMGNFaSQgWO3QwaIlD3A9uP0O7HAgzGX8ydC0TiOhKNfo-wnd0Zmvaeag26FCXqAnEqAl72t-m11NsXRWWm9iGgL_kWcLuN1befyovEf-jwhKmBvY_kGV4p5qfR5ZyqhlPp-4Je90NlV9y_f3PP_y_5o_YTR6HdpHy4oDtrleb8Bhh4to9ibPCTxRjY24 priority: 102 providerName: Springer Nature
Title	International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?
URI	https://link.springer.com/article/10.1186/s12944-023-01833-z https://www.ncbi.nlm.nih.gov/pubmed/37231413 https://www.proquest.com/docview/2827110273 https://www.proquest.com/docview/2820016620 https://hal.science/hal-04190781 https://pubmed.ncbi.nlm.nih.gov/PMC10210460 https://doaj.org/article/2b99aac6ce9a46aa88b02a157d2a904c
Volume	22
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVFSB databaseName: Free Full-Text Journals in Chemistry customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: HH5 dateStart: 20020101 isFulltext: true titleUrlDefault: http://abc-chemistry.org/ providerName: ABC ChemistRy – providerCode: PRVADU databaseName: BioMed Central Open Access Free customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: RBZ dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: KQ8 dateStart: 20020101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: KQ8 dateStart: 20020901 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ (Directory of Open Access Journals) customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: DOA dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEBS databaseName: EBSCOhost Academic Search Ultimate customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: ABDBF dateStart: 20020101 isFulltext: true titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn providerName: EBSCOhost – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: DIK dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: GX1 dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: M~E dateStart: 20020101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: RPM dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1476-511X dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: M48 dateStart: 20020901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature HAS Fully OA customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: AAJSJ dateStart: 20021201 isFulltext: true titleUrlDefault: https://www.springernature.com providerName: Springer Nature – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: C6C dateStart: 20021201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1476-511X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0020766 issn: 1476-511X databaseCode: U2A dateStart: 20021201 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELf2ISFeEGx8BEZ1IAQPEEgdx3GQ0NRNmybEJoSo1DfLdr2tYktH2yG6_4j_kjvnA4UBEi-VErvJOXfn-53tu2PsmZAuo5LGsXdGxUIqExvOXYzgNzk2Nuc-RKUdHsmDoXg_ykYrrCl3VH_A-R9dO6onNZydvf7-dbmNCv8uKLySb-Zos4SI0fqgY6zSNL5aZetomThJ-aFodxU4-uxVtFEuYwQaoyaI5o_P6BiqkM-_nbVXT-nQ5HVEev1g5W-7q8Fo7d9mt2q0CYNKPO6wFV9usM1BiZ72-RKeQzj_GRbWN9iNw3qbfZP96KwTQhNJBRchGWc5h-kxjJeIUKvysgbO20M0MCmhztU6B1rkBVel34Uvk3Hpl1DvCAEFr82g9ChMgQCgM2hvYTKHyQKo4j0splAF1sDJJSXjQtKA_PdzfE9VCWq-fZcN9_c-7x7EdU2H2KGns4hlPk4KlXFlrLU-RfAhjHPjwqWFF4nwhbRGmKRv0Lg6a4sit84Y6wtlM-8Tl95ja-W09A8YuMRRZkWeOYmwKrWKoIsopFPSHhdGRazfMFC7OuE51d0408HxUVJXTNfIdB2Yrq8i9rL9z0WV7uOfvXdILtqelKo73JjOTnSt-ZrjIIxx0vnCCGmMUjbhpp_lY26KRLiIvSCp0iTiSJ4zdVwEDpJSc-kBYrqccC4OaKvTEycC12l-inLZIeZg8EHTvUQg7stV_1sfn9GIrW6UTaPbnSMnEMlG7EnbTI-nE3iln16GPuQeSJ5E7H4l5e2r0hy9BGRYxFRH_ju0dFvKyWnIZU6V5WlvPmKvGlX5Rdffv_zD_-LTI3aTB83OYp5tsbXF7NI_Riy5sD22mo_yHlvf2Tv6-AmvduVuL6zL9MLUgb9DPvgJI_l0nQ
linkProvider	Scholars Portal
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbaIgEXBC2PQIEB8ThA1GziOA4SqpZHtaWPUyvtzdhet13BZstmF7T9R1z4jcw4yVahordeY68z3pnMw575hrEXXNiUWhqHzmoZciF1qOPYhuj8RkfaZLHzVWl7-6J3yL_00_4S-9PUwlBaZaMTvaIejC2dkW9gaJChqUJru3n6I6SuUXS72rTQqMRix81_YchWvt_-hPx9Gcdbnw8-9sK6q0Bo0deehiIbRLlMY6mNMS7BNbm2dpDbJHc84i4XRnMddTSqd2tMnmfGam1cLk3qXGQTXHeZXeNJxAmrP-ufB3hRJkRTmCPFRom2lPMQrSIG7DJJwrOW8fM9AhaWYPmEEjEverkXkzX_ubH1hnDrNrtVe7DQrUTuDltyxSpb6xYYvY_m8Ap8Tqk_rF9l1_fqq_s19rt19ghNdRaceoDPooTxEQzm6PVWLWs1jBaJOTAsoMZ_LYEOjsFWkL7wbTgo3BzqWyaggrgJFA4F1BMAlNf2DoYlDKcwHY4cTMdQFevA8YwAvpA0oDOBEb6n6i5Vbt5lh1fC0XtspRgX7gEDG1lCa4xTK9BVS4wkd4jnwkphjnItA9ZpGKhsDaJOvTy-Kx9MSaEqpitkuvJMV2cBe7P4zWkFIXLp7A8kF4uZBP_tH4wnx6rWJirGTWhthXW55kJrKU0U606aDWKdR9wG7DVJlSIlheRZXdda4CYJ7kt10U_MyHfGDa23ZqJysa3h5yiXLWJ63V1FzyKOvmQmOz87uEYjtqrWgKU6_14D9mwxTMtTVl_hxjM_h0IOEUcBu19J-eJVSYaRBzIsYLIl_y1a2iPF8MTjo1O3errvD9jb5lM5p-v___zDy7fxlN3oHeztqt3t_Z1H7GbsP-s0jNN1tjKdzNxjdE6n5onXCMC-XrUK-gt6paSH
linkToPdf	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZoK1VcELQ8AgUGhOAAUbOJ49hcUHhUy9JWSFCpN8t2vO0KNrva7CJt_xH_krHzgFBA4po4yTgztr-xZ74h5AllJnUljUNrFA8p4ypUcWxCBL_RWOkstj4r7eiYDU_o6DQ9_SWL30e7t0eSdU6DY2kql_vzYlwPcc72K1ylKA1xvUFXmCdJeLFBtngqGLpfW3k--jTqnC7001mbLPPHJ3sLkuft72bnjXMXHHkZeV4OoPztFNUvTgfXybUGVUJem8ENcsWWO2Q3L9Gjnq7hKfg4T7-BvkO2j5rj9F3yvbcfCG3GFMw96WZZwWwMxRqRaF1GVsG0C5aBSQkNJ2sFbjMXTE2zC18mRWnX0Jz8gEtSW0Bp0Wi8AOBizV7CpILJElxle1jOoE6ggbOVI91C0cD56VP8Tl3xqXp1k5wcvPv8Zhg2tRtCgx7NMmRZEQmexlxprW2CIIMqYwphEmFpRK1gWlEVDRQuokZrITJtlNJWcJ1aG5nkFtksZ6W9Q8BExjEoxqlhCJ8SzR1EoYIZzvRYKB6QQatAaRpic1df46v0Dg5nsla6RKVLr3R5EZDn3TPzmtbjn61fO7voWjpKbn9htjiTzQiXMXZCKcOMFYoypTjXUawGaVbESkTUBOSZsyrpJg4Uz6gm_wE76Si4ZI7YLXN4Fju012uJA970bj9Gu-wJM8wPpbsWUcR3GR98G-A7WrOVzaxUSXSvM9QEItaAPOpuu9e7SLvSzla-jXMDWBwF5HZt5d2nkgy9AVRYQHjP_nuy9O-Uk3PPWe4qyLsz-IC8aIfKT7n-_ufv_l_zh2T749sDefj--MM9cjX2ozwN43SPbC4XK3sf8eNSP2imiB9ZkWvs
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=International+practice+patterns+of+dyslipidemia+management+in+patients+with+chronic+kidney+disease+under+nephrology+care%3A+is+it+time+to+review+guideline+recommendations%3F&rft.jtitle=Lipids+in+health+and+disease&rft.au=Calice-Silva%2C+Viviane&rft.au=Muenz%2C+Daniel&rft.au=Wong%2C+Michelle+M.+Y.&rft.au=McCullough%2C+Keith&rft.date=2023-05-25&rft.issn=1476-511X&rft.eissn=1476-511X&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs12944-023-01833-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12944_023_01833_z
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-511X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-511X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-511X&client=summon